Breaking News

DSM to Manufacture BiAqua’s Ferritin

DSM BioSolutions, Royal DSM's microbial fermentation contract manufacturing business, and BiAqua B.V., a bio-based solutions provider for serious water contamination issues, have entered into an agreement for strain development, process development and pr

DSM BioSolutions, Royal DSM’s microbial fermentation contract manufacturing business, and BiAqua B.V., a bio-based solutions provider for serious water contamination issues, have entered into an agreement for strain development, process development and production of “BiAqua Ferritin” for BiAqua’s core technology to address bio-fouling and arsenic contamination in the water sector.

DSM has successfully started strain and process development of BiAqua Ferritin at its process development facility in Delft, The Netherlands and will soon begin scale-up and manufacturing at its microbial fermentation biotech facility in Capua, Italy. The BiAqua Ferritin will be used for BiAqua water contamination studies in collaboration with water companies and consumers worldwide to reduce bacterial and arsenic contamination.

Nityen Lal, managing director of BiAqua, said, “DSM has assembled a first class team to help us drastically optimize the cost of production on the basis of their expertise, proprietary tools and technology. This should enable BiAqua to offer an affordable bio-based solution to the market in the short term.”

Villaume Kal, vice president of DSM BioSolutions said, “We are delighted to work with BiAqua, an innovative and progressive company developing bio-based solutions to worldwide water contamination issues. Our technology, operational excellence and outstanding regulatory compliance record allows us to serve this important customer and to develop and manufacture their Ferritin product.”

Financial terms were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters